Pharmacokinetic interaction between the flavonoid luteolin and γ-hydroxybutyrate in rats: Potential involvement of monocarboxylate transporters

AAPS Journal

Volumn 10, Issue 1, 2008, Pages 47-55

  Wang, Xiaodong ^a   Wang, Qi ^b   Morris, Marilyn E ^a  

^a UNIVERSITY AT BUFFALO   (United States)

^b BRISTOL MYERS SQUIBB   (United States)

Author keywords

hydroxybutyrate; Luteolin; MCT; Pharmacokinetic interactions

Indexed keywords

4 HYDROXYBUTYRIC ACID; LUTEOLIN; MONOCARBOXYLATE TRANSPORTER;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG MEGADOSE; DRUG METABOLISM; DRUG URINE LEVEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VIVO STUDY; INHIBITION KINETICS; KIDNEY CLEARANCE; LIQUID CHROMATOGRAPHY; LOW DRUG DOSE; MALE; METABOLIC INHIBITION; NONHUMAN; PHARMACODYNAMICS; RAT; SLEEP TIME; TANDEM MASS SPECTROMETRY;

ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; FLAVONOIDS; LUTEOLIN; MALE; MONOCARBOXYLIC ACID TRANSPORTERS; RATS; RATS, SPRAGUE-DAWLEY; SODIUM OXYBATE;

EID: 51249090528     PISSN: 15507416     EISSN: None     Source Type: Journal    
DOI: 10.1208/s12248-007-9001-8     Document Type: Article

References (37)

1. A. P. Halestrap, D. Meredith. The SLC16 gene family-from monocarboxylate transporters (MCTs) to aromatic amino acid transporters and beyond. Pflugers Arch. 447(5)619-628 (2004).
2. A. P. Halestrap, N. T. Price. The proton-linked monocarboxylate transporter (MCT) family: Structure, function and regulation. Biochem. J. 343(Pt 2)281-299 (1999).
3. I. Tamai, Y. Sai, A. Ono, Y. Kido, H. Yabuuchi, H. Takanaga, E. Satoh, T. Ogihara, O. Amano, S. Izeki, A. Tsuji. Immunohistochemical and functional characterization of pH-dependent intestinal absorption of weak organic acids by the monocarboxylic acid transporter MCT1. J. Pharm. Pharmacol. 51(10)1113-1121 1999.
4. A. Okamura, A. Emoto, N. Koyabu, H. Ohtani, Y. Sawada.Transport and uptake of nateglinide in Caco-2 cells and its inhibitory effect on human monocarboxylate transporter MCT1. Br. J. Pharmacol. 137(3)391-399 (2002).
5. K. Nagasawa, K. Nagai, Y. Sumitani, Y. Moriya, Y. Muraki, K. Takara, N. Ohnishi, T. Yokoyama, S. Fujimoto. Monocarboxylate transporter mediates uptake of lovastatin acid in rat cultured mesangial cells. J. Pharm. Sci. 91(12)2605-2613 (2002).
6. C. Manach, A. Scalbert, C. Morand, C. Remesy, L. Jimenez. Polyphenols: food sources and bioavailability. Am. J. Clin. Nutr. 79(5)727-747 (2004).
7. K. Horvathova, L. Novotny, D. Tothova, A. Vachalkova. Determination of free radical scavenging activity of quercetin, rutin, luteolin and apigenin in H2O2-treated human ML cells K562. Neoplasma. 51(5)395-399 (2004).
8. A. Kotanidou, A. Xagorari, E. Bagli, P. Kitsanta, T. Fotsis, A. Papapetropoulos, C. Roussos. Luteolin reduces lipopolysaccharide-induced lethal toxicity and expression of proinflammatory molecules in mice. Am. J. Respir. Crit. Care Med. 165(6)818-823 (2002).
9. Q. Wang, M. E. Morris. Flavonoids modulate monocarboxylate transporter-1-mediated transport of gamma-hydroxybutyrate in vitro and in vivo. Drug Metab. Dispos. 35(2)201-208 (2007).
10. G. K. Dresser, D. G. Bailey, B. F. Leake, U. I. Schwarz, P. A. Dawson, D. J. Freeman, R. B. Kim. Fruit juices inhibit organic anion transporting polypeptide-mediated drug uptake to decrease the oral availability of fexofenadine. Clin. Pharmacol. Ther. 71(1)11-20 (2002).
11. J. S. Choi, H. K. Choi, S. C. Shin. Enhanced bioavailability of paclitaxel after oral coadministration with flavone in rats. Int. J. Pharm. 275(1-2)165-170 (2004).
12. Y. H. Wang, P. D. Chao, S. L. Hsiu, K. C. Wen, Y. C.Hou. Lethal quercetin-digoxin interaction in pigs. Life Sci. 74(10)1191-1197 (2004).
13. X. Wang, M. E. Morris. Effects of the flavonoid chrysin on nitrofurantoin pharmacokinetics in rats: Potential involvement of ABCG2. Drug Metab. Dispos. 35(2)268-274 (2007).
14. Q. Wang, I. M. Darling, M. E. Morris. Transport of gamma-hydroxybutyrate in rat kidney membrane vesicles: Role of monocarboxylate transporters J. Pharmacol. Exp. Ther. 318(2)751-761 (2006).
15. M. Mamelak, M. B. Scharf, M. Woods. Treatment of narcolepsy with gamma-hydroxybutyrate. A review of clinical and sleep laboratory findings. Sleep. 9(1 Pt 2)285-289 (1986).
16. K. R. Drasbek, J. Christensen, K. Jensen. Gamma-hydroxybutyrate-a drug of abuse. Acta Neurol. Scand. 114(3)145-156 (2006).
17. P. E. Mason, W. P. Kerns 2nd. Gamma hydroxybutyric acid (GHB) intoxication. Acad Emerg. Med. 9(7)730-739 (2002).
18. J. Lettieri, H. L. Fung. Absorption and first-pass metabolism of 14C-gamma-hydroxybutyric acid. Res. Commun. Chem. Pathol. Pharmacol. 13(3)425-437 (1976).
19. J. T. Lettieri, H. L. Fung. Dose-dependent pharmacokinetics and hypnotic effects of sodium gamma-hydroxybutyrate in the rat. J. Pharmacol. Exp. Ther. 208(1)7-11 (1979).
20. M. E. Morris, K. Hu, Q. Wang. Renal clearance of gamma-hydroxybutyric acid in rats: Increasing renal elimination as a detoxification strategy. J. Pharmacol. Exp. Ther. 313(3)1194-1202 (2005).
21. P. Palatini, L. Tedeschi, G. Frison, R. Padrini, R. Zordan, R. Orlando, L. Gallimberti, G. L. Gessa, S. D. Ferrara. Dose-dependent absorption and elimination of gamma-hydroxybutyric acid in healthy volunteers. Eur. J. Clin. Pharmacol. 45(4)353-356 (1993).
22. C. Arena, H. L. Fung. Absorption of sodium gamma-hydroxybutyrate and its prodrug gamma-butyrolactone: Relationship between in vitro transport and in vivo absorption. J. Pharm. Sci. 69(3)356-358 (1980).
23. L. Li, H. Jiang, H. Wu, S. Zeng. Simultaneous determination of luteolin and apigenin in dog plasma by RP-HPLC. J. Pharm. Biomed. Anal. 37(3)615-620 (2005).
24. T. Chen, L. P. Li, X. Y. Lu, H. D. Jiang, S. Zeng. Absorption and excretion of luteolin and apigenin in rats after oral administration of Chrysanthemum morifolium extract. J. Agric. Food Chem. 55(2)273-277 (2007).
25. H. L. Fung, E. Haas, J. Raybon, J. Xu, S. M. Fung. Liquid chromatographic-mass spectrometric determination of endogenous gamma-hydroxybutyrate concentrations in rat brain regions and plasma. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 807(2)287-291 (2004).
26. B. Ferrier, M. Martin, B. Janbon, G. Baverel. Transport of beta-hydroxybutyrate and acetoacetate along rat nephrons: A micropuncture study. Am. J. Physiol. 262(5 Pt 2)F762-769 (1992).
27. D. K. Van Sassenbroeck, P. De Paepe, F. M. Belpaire, W. A.Buylaert. Characterization of the pharmacokinetic and pharmacodynamic interaction between gamma-hydroxybutyrate and ethanol in the rat. Toxicol. Sci. 73(2)270-278 (2003).
28. B. H. Havsteen.The biochemistry and medical significance of the flavonoids. Pharmacol. Ther. 962-367-202 (2002).
29. C. M. Kruijtzer, J. H. Beijnen, H. Rosing, W. W. ten Bokkel Huinink, M. Schot, R. C. Jewell, E. M. Paul, J. H. Schellens. Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918. J. Clin. Oncol. 20(13)2943-2950 (2002).
30. A. Sparreboom, M. C. Cox, M. R. Acharya, W. D. Figg. Herbal remedies in the United States: Potential adverse interactions with anticancer agents. J. Clin. Oncol. 22(12)2489-2503 (2004).
31. Q. Wang, Y. Lu, M. E. Morris. Monocarboxylate transporter (MCT) mediates the transport of gamma-hydroxybutyrate in human kidney HK-2 cells. Pharm. Res. 24(6)1067-1078 (2007).
32. I. Bhattacharya, K. M. Boje. GHB (gamma-hydroxybutyrate) carrier-mediated transport across the blood-brain barrier. J. Pharmacol. Exp. Ther. 311(1)92-98 (2004).
33. D. R. Ferry, A. Smith, J. Malkhandi, D. W. Fyfe, P. G. deTakats, D. Anderson, J. Baker, D. J. Kerr. Phase I clinical trial of the flavonoid quercetin: Pharmacokinetics and evidence for in vivo tyrosine kinase inhibition. Clin. Cancer Res. 2(4)659-668 (1996).
34. Y. Li, W. S. Pan, S. L. Chen, H. X. Xu, D. J. Yang, A. S. Chan. Pharmacokinetic, tissue distribution, and excretion of puerarin and puerarin-phospholipid complex in rats. Drug Dev. Ind. Pharm. 32(4)413-422 (2006).
35. Y. C. Li, C. F. Hung, F. T. Yeh, J. P. Lin, J. G. Chung. Luteolin-inhibited arylamine N-acetyltransferase activity and DNA-2-aminofluorene adduct in human and mouse leukemia cells. Food Chem. Toxicol. 39(7)641-647 (2001).
36. L. P. Xie, Q. X. Chen, H. Huang, H. Z. Wang, R. Q. Zhang. Inhibitory effects of some flavonoids on the activity of mushroom tyrosinase. Biochemistry (Mosc). 68(4)487-491 (2003).
37. D. W. Boulton, U. K. Walle, T. Walle. Extensive binding of the bioflavonoid quercetin to human plasma proteins. J. Pharm. Pharmacol. 50(2)243-249 (1998).